What We Do
We operate a CLIA lab in Boston. We provide convenient at-home/mail-in Hydrogen/Methane BREATH testing to uncover the root causes of high prevalence chronic gut issues of the small intestine including:
- SIBO/IMO breath testing (we offer glucose or lactulose substrates)
- Lactose intolerance breath testing
- Fructose malabsorption breath testing
- Sucrose intolerance breath testing
We deliver binary, clinically supported results to both practitioners and patients:
-
Rapid: Results typically available within 24 hours of sample receipt.
-
Accurate: best-in-class, lab-verified technology – powered by QuinTron.
-
Affordable: Priced competitively for accessibility.
Want your practitioner to provide Gut Health Breath Testing? Practitioner Referral
in brief: gut health breath testing
The problem: millions live with unexplained gut symptoms because the standard test looks in the wrong part of the body — a four-year average path to diagnosis, and $111.8B a year in system-wide cost.
The blind spot: the conditions being missed are specific and treatable. Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Methanogen Overgrowth (IMO), Lactose Intolerance, Fructose Malabsorption, and Sucrose Intolerance. A stool test cannot see any of them.
The opportunity: a proven small-intestine breath test that we are getting it into the hands of practitioners — wellness, functional, and longevity doctors — who are best positioned to use it, at scale.
The stakes: A missed small intestine problem can silently limit how well other treatments work — from hormone therapy to GLP-1 weight-loss drugs, which recent research links to nearly three times the rate of small intestine overgrowth.
Community: We do this bringing together a community of practitioners learning from other practitioners and clinical experts, not as a sales operation. That’s deliberate: doctors trust other doctors, not a lab’s sales pitch, and every clinical decision stays with the licensed provider treating the patient. It’s also simply the right way to do this responsibly.
Vision for Wellness, preventative health & Longevity
While focused initially on chronic gut health diagnostics, AllClear’s platform and strategy are designed for nimble, multispecialty growth. We are targeting future expansion into oncology, neurology, pharmacogenetics, stem cell, and other diagnostic fields. This diversified diagnostic portfolio offers practitioners considerable upside as bio-venture pipelines mature and new meaningful and actionable diagnostics gain regulatory approval and commercial viability.
Meet the Team
We have formed a core team of highly qualified, entrepreneurial operators who are supported by a noteworthy advisory team. AllClear exists to help practitioners deliver better patient outcomes, more rapidly and affordably. We start with the gut because when the gut is out of balance, every downstream protocol — hormone, nutritional, weight, longevity, autoimmune — has to work harder. Rapid, accurate, affordable gut diagnostics give practitioners the foundation their other protocols depend on.
Advisors
Meet Our New Advisors
Gabor Bethlendy is a Boston-based diagnostics operator who has built and exited platforms squarely in AllClear’s lane. He founded Meenta, the first national marketplace for diagnostic and laboratory services, scaling it to ~$15M in revenue across 100+ labs and delivering COVID testing for the U.S. Olympic Team — the same practitioner-and-enterprise motion AllClear runs today. Earlier, he co-founded Parabase Genomics, a rapid precision-diagnostics platform acquired by Quest Diagnostics and now used in clinical care. He is currently Founder & CEO of GRAVL, a data infrastructure layer for scientific services, and Senior Advisor for Life Sciences M&A at Kairos Ventures. Gabor advises AllClear on diagnostics platform strategy, lab and practitioner channel expansion, and strategic transactions.
Dr. Ilana Gurevich is a naturopathic physician, Fellow of the American Board of Naturopathic Gastroenterology, and licensed acupuncturist. Based in Portland, she specializes in IBD, IBS, SIBO, and other functional GI disorders. She co‑hosts “The Turd Nerds” and “The Point of Medicine” podcasts, lectures nationally on integrative gastroenterology, and mentors clinicians managing complex GI cases. Named a Portland Monthly “Top Doc” multiple years, she received the 2022 Borborygmus Lifetime Achievement Award for advancing naturopathic gastroenterology.
Bonnie T. Wilkinson, a seasoned financial and operations executive, has held leadership roles including Interim Head of Financial Systems and Internal Audit & Compliance IT Lead at Ginkgo Bioworks, where she supported a successful SPAC IPO valued at $15B. With deep experience across public and private companies—from early-stage ventures to Fortune 500s—Bonnie brings expertise in biotech, pharma, medical devices, high-tech, manufacturing, and non-profit sectors. She is advising AllClear on operational systems evolution and strategic financial planning, with a focus on scalable infrastructure and compliance.
Alex Glovsky, President of Glic Health LLC (provider of prescription discount programs and pharmacy consulting services), has a background in finance and M&A from his previous law practice at Nutter. He is helping provide high level guidance on our longer-term strategy to penetrate traditional insurance-driven healthcare systems more effectively, as we prepare for our broader portfolio launch.
Phillip Thomas, With over 30 years of experience as a CEO in both public and private companies, Phillip specializes in operational turnarounds, corporate growth, and leadership development, particularly for manufacturing, diagnostics, and technology firms. As CEO of Boston Business Group and Chair of multiple Boston Region Vistage Peer Groups, he works closely with C-suite executives to enhance leadership skills and drive valuation growth. His expertise spans negotiation, mediation, conflict resolution, and corporate transformation, supported by executive education at Harvard Law School. Beyond business, he is a passionate beekeeper, drawing leadership and teamwork parallels from these remarkable insects.
Joe Knowles: CEO/Founder, Institute for Health Metrics; Harvard School of Public Health
George Lloyd: EVP, Investments & General Counsel, RoyaltyPharma
John Collins: CEO GMBC; founder Nolij Corp; Board of Trustees, Northeast Hospital (Beth Israel Lahey) and Care Dimensions
John Egan: Red Barn Advisory, Founder and CEO; COO Family Office; Wall St.
Nesbitt Hagood: Managing General Partner, Tenon Ventures; CEO Triib; VP Technology, Qualcomm, MIT tenured professor, Innovator.
Bruce Journey: Co-Founder DataXu (retired); CEO, Technology Review, Inc. an MIT Enterprise
Meet Our Clients
Our Mission
AllClear Healthcare is paving the way for practitioner-based education, learning, and progress through continuing education, research, and a network of like-minded industry professionals and solutions.
AllClear Healthcare’s mission is to positively disrupt unmet needs within our underperforming healthcare system. We provide comprehensive, patient-focused and convenient testing options that give you rapid, accurate and affordable results – often in just minutes. We are scaling our digital, customer-centric platform to provide exceptional diagnostic solutions for a variety of newly emerging individual and public health needs.
Through our health diagnostics efforts, we have also had the opportunity to significantly contribute to the safety and productivity of our local and national business communities to keep communities, organizations, and businesses up and running safely, confidently, and productively.
AllClear Healthcare is committed to bringing the most accurate gastrointestinal and other health testing possible, including small intestinal bacterial overgrowth (SIBO)/ Intestinal Methanogen Overgrowth (IMO) breath testing and testing for diseases of carbohydrate metabolism.
AllClear Healthcare, a best-in-class testing company, was founded at the height of the pandemic to offer FDA-approved rapid, accurate, and affordable COVID-19 testing. Soon, we extended our respiratory testing offerings to include RSV, influenza A&B, and strep.
Collaborating with healthcare practitioners and patients, we found that the problem of slow and inefficient testing options exists in the diagnostics world for gastrointestinal illnesses as well.
Gastrointestinal issues are rampant. 35.4 million people visit their primary care doctor each year with gastrointestinal diseases as the primary diagnosis (1). Digestive issues are the 13th leading cause of disability-adjusted life year (DALY) (2).
Yet, SIBO/IMO diseases of carbohydrate metabolism, and other gastrointestinal issues go undiagnosed and under-diagnosed because of slow, inefficient, invasive, and expensive testing options (3).
Our main focus has expanded to offer fast, accurate, and affordable Hydrogen/Methane breath testing solutions for gastrointestinal issues — a much-missing piece in medicine. We now help practitioners get their patients treatment faster with At-home, Mail-in testing that is highly accurate and affordable for:
- SIBO/IMO breath testing (we offer glucose or lactulose substrates)
- Lactose intolerance breath testing
- Fructose malabsorption breath testing
- Sucrose intolerance breath testing
We believe these new testing protocols can help your practice improve efficiency and accelerate the time to better health by triaging patients rapidly and helping to reduce the cost of diagnostics for your patients.
Disclaimer
General Use and Medical Advice Disclaimer
The information provided in this “About Us” section and elsewhere on this website is for general informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
Always seek the advice of your physician or another qualified healthcare provider with any questions you may have regarding a medical condition or treatment, before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website. Reliance on any information provided by AllClear Healthcare is solely at your own risk.
Diagnostics and Regulatory Disclaimer
AllClear Healthcare operates a CLIA-certified laboratory. Our tests are designed to provide data to licensed healthcare practitioners for use as a tool in their diagnostic process. The tests offered are not intended to self-diagnose or treat any disease or medical condition. A physician’s order is required for testing.
Forward-Looking Statements Disclaimer
Statements made on this page regarding future growth areas (such as oncology, neurology, pharmacogenetics, etc.) reflect the strategic long-term goals and vision of AllClear Healthcare. These are forward-looking statements subject to various risks and uncertainties. Our future performance and the actual development of these new diagnostic portfolios may differ materially from current expectations. We do not assume any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
